|
|
Article: Human Genome Sciences Announces Third Quarter 2009 Financial Results and Key Developments.(Financial report)
- Article from:
- Hepatitis Weekly
- Article date:
- November 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Human Genome Sciences, Inc. (Nasdaq:HGSI) announced financial results for the quarter ended September 30, 2009, and provided highlights of recent key developments (see also Human Genome Sciences, Inc.).
"In the third quarter, we made outstanding progress on the path to commercialization of our late-stage products and substantially improved our financial strength," said H. Thomas Watkins, President and Chief Executive Officer. "The positive Phase 3 results we have seen for both BENLYSTA for systemic lupus and ZALBIN for chronic hepatitis C suggest that each of these products represents a significant therapeutic and commercial opportunity. Assuming the second Phase ...